Second Death In Zafgen’s Obesity Drug Trial Raises Pulmonary Embolism Safety Concern
This article was originally published in The Pink Sheet Daily
Executive Summary
Two patients who died during beloranib clinical trial had pulmonary emboli; sponsors of other obesity drugs have focused on potential cardiovascular risk.